ERIS Lifesciences Ltd

ERIS Lifescience Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

ERIS Lifesciences Ltd

₹ 1,074 0.33%
26 Jul - close price
eris.co.in BSE: 540596 NSE: ERIS
About

ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]

Key Points

Product Offerings
The company offers 350+ pharmaceutical products/ formulations in the Indian pharmaceutical market.[1] It is a pure-play domestic branded formulations company with no export presence.[2]

Website BSE NSE
  • Market Cap ₹ 14,608 Cr.
  • Current Price ₹ 1,074
  • High / Low ₹ 1,099 / 767
  • Stock P/E 37.3
  • Book Value ₹ 190
  • Dividend Yield 0.68 %
  • ROCE 11.3 %
  • ROE 16.4 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Tax rate seems low
  • Company might be capitalizing the interest cost
  • Debtor days have increased from 61.2 to 76.7 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
278 349 360 332 306 399 461 423 403 467 505 486 551
184 223 220 210 209 269 309 286 284 297 324 311 402
Operating Profit 95 127 140 122 97 129 151 137 119 170 181 176 148
OPM % 34% 36% 39% 37% 32% 32% 33% 32% 30% 36% 36% 36% 27%
2 6 7 5 8 3 5 2 1 1 3 4 15
Interest 1 1 1 1 1 7 7 3 9 17 16 18 33
Depreciation 11 15 15 17 18 23 29 30 35 41 42 46 54
Profit before tax 85 117 131 109 85 101 121 107 76 112 126 116 77
Tax % 19% 9% 9% 8% 6% 8% 1% 6% 19% 17% 3% 12% -4%
68 107 118 101 80 93 119 100 61 94 122 101 80
EPS in Rs 5.03 7.86 8.71 7.41 5.91 6.96 8.85 7.49 4.81 6.98 9.07 7.55 5.22
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
393 509 546 597 750 856 982 1,074 1,212 1,347 1,685 2,009
307 414 427 425 480 533 637 702 781 858 1,146 1,334
Operating Profit 86 95 118 172 269 322 345 372 431 489 539 675
OPM % 22% 19% 22% 29% 36% 38% 35% 35% 36% 36% 32% 34%
1 9 7 3 25 26 31 12 9 22 9 24
Interest 1 0 0 0 1 11 23 2 2 4 26 85
Depreciation 3 5 16 20 23 26 36 50 43 65 117 183
Profit before tax 83 98 109 154 270 312 317 331 394 442 405 431
Tax % 30% 28% 18% 13% 9% 6% 8% 11% 10% 8% 8% 8%
58 71 89 135 247 295 291 297 355 406 374 397
EPS in Rs 4,232.73 5,121.45 6,489.45 9,714.18 17.95 21.39 21.15 21.84 26.16 29.88 28.10 28.82
Dividend Payout % 0% 0% 0% 63% 0% 0% 0% 13% 21% 20% 26% 0%
Compounded Sales Growth
10 Years: 15%
5 Years: 15%
3 Years: 18%
TTM: 19%
Compounded Profit Growth
10 Years: 19%
5 Years: 6%
3 Years: 4%
TTM: 6%
Stock Price CAGR
10 Years: %
5 Years: 22%
3 Years: 13%
1 Year: 38%
Return on Equity
10 Years: 25%
5 Years: 21%
3 Years: 19%
Last Year: 16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 0 0 0 0 14 14 14 14 14 14 14 14
Reserves 106 176 266 299 553 848 1,137 1,283 1,563 1,895 2,182 2,573
3 1 1 0 1 377 176 0 7 84 877 2,781
63 94 91 98 124 170 175 205 202 233 337 1,681
Total Liabilities 172 271 357 397 692 1,408 1,502 1,502 1,785 2,226 3,410 7,049
27 75 72 71 232 771 761 875 854 918 2,568 4,328
CWIP 0 0 0 0 0 0 3 4 2 27 22 19
Investments 47 84 167 190 303 365 356 78 294 520 37 16
98 112 119 136 157 271 383 544 636 761 783 2,686
Total Assets 172 271 357 397 692 1,408 1,502 1,502 1,785 2,226 3,410 7,049

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
38 90 90 131 200 235 223 271 375 378 292 486
-36 -83 -92 -44 -184 -590 -5 123 -323 -320 -975 -1,855
-3 -2 0 -84 -24 363 -221 -335 -82 -45 688 1,380
Net Cash Flow -1 5 -2 4 -8 8 -3 60 -30 14 5 11

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 15 16 16 16 24 28 31 53 42 44 63 77
Inventory Days 214 166 223 178 195 178 196 148 145 166 136 182
Days Payable 109 138 142 92 134 247 200 213 157 166 129 258
Cash Conversion Cycle 120 43 97 102 84 -40 28 -12 30 44 70 0
Working Capital Days 31 7 15 9 23 -13 -17 59 64 76 92 83
ROCE % 98% 64% 47% 53% 60% 34% 26% 25% 27% 25% 17% 11%

Shareholding Pattern

Numbers in percentages

4 Recently
Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
52.68% 52.66% 52.66% 52.30% 52.29% 52.70% 52.86% 52.86% 54.91% 54.90% 54.90% 54.88%
13.60% 13.34% 13.31% 15.35% 15.39% 15.50% 14.86% 13.78% 13.20% 13.13% 14.27% 14.59%
9.94% 10.37% 10.50% 10.66% 10.69% 9.95% 10.02% 10.73% 14.52% 14.55% 15.63% 16.23%
23.78% 23.62% 23.52% 21.69% 21.63% 21.85% 22.27% 22.63% 17.37% 17.41% 15.20% 14.30%
No. of Shareholders 49,83354,22357,06151,63948,05546,74645,93144,16942,24546,49651,75344,176

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls